BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, February 17, 2026
Home
»
Newsletters
» BioWorld
BioWorld
April 14, 2009
View Archived Issues
Matrix Metalloproteinase Does About-Face in Melanoma Study
Read More
NewCo News: GliaMed Gets a Facelift as it Moves into Wound Healing
Read More
Record-High Side Effects Reported to FDA in 2008
Read More
Other News To Note
Read More
Appointments And Advancements
Read More
FDA Reviews Solzira; XenoPort Exercises Co-Promote Option
While the FDA reviews a new drug application for Solzira (gabapentin enacarbil) in restless legs syndrome, XenoPort Inc. exercised its option to co-promote the drug in the U.S. with partner GlaxoSmithKline plc. (BioWorld Today)
Read More
Cell Therapeutics Raises $15M for its Late-Stage Development
Read More
